Bo Mi Ku

The paper develops an in silico-in vitro workflow to generate high-affinity antibodies targeting the KRAS(G12D)-MHC I complex, achieving nanomolar affinity and specific T cell activation.

The paper computationally designs monomeric Fc variants with distinct pH-responsive FcRn-binding profiles, showing enhanced binding at acidic pH and weak binding at neutral pH.

This study links tumor and immune cell profiles in NSCLC patients to their response to immune checkpoint inhibitors, finding higher CD4+ regulatory T cells and NF-kB/STAT3 activity in non-responders.